| 시타글립틴의 혈당강하효과에 영향을 미치는 인자 |
|
김건우, 김재현, 이미영, 신장열, 신영구, 하은호, 정춘희 |
|
|
| Factors Influencing Glycemic Control Response of Sitagliptin. |
|
Gun Woo Kim, Jae Hyun Kim, Mi Young Lee, Jang Yel Shin, Young Goo Shin, Eun Ho Ha, Choon Hee Chung |
1Department of Internal Medicine, Yonsei University Wonju College of Medicine, Wonju, Korea. cchung@yonsei.ac.kr
2Department of Information & Statistics, Yonsei University College of Science of Technology, Wonju, Korea. |
|
|
| Abstract |
BACKGROUND
Dipeptidyl peptidase 4 (DPP-4) inhibitors are proposed to reduce blood glucose in type 2 diabetes by prolonging the activity of circulating incretins. However, the factors that affect the efficacy of sitagliptin have not yet been demonstrated. Therefore, we studied them in a Korean population. METHODS: We performed a retrospective analysis in patients taking sitagliptin in Wonju Christian Hospital. One hundred-fifty patients whose serum HbA1c ranged from 6.5% to 11% participated in this study. These patients were divided into two groups: responder and non-responder. The responder group consisted of subjects with glucose lowering greater than 5% of baseline HbA1c. The others were in non-responder group. We analyzed anthropometric data and biochemical markers in all groups, then compared responder group and non-responder group by logistic regression. RESULTS: The change in HbA1c level across all groups was 8.25 +/- 0.82% to 7.64 +/- 1.03% (P value = 0.000). There were 93 and 57 patients in responder and non-responder group, respectively. The responder group had lower BMI, body fat (kg), body fat (%) than the non-responder group (P value = 0.024, P value = 0.029, P value = 0.025), and the HbA1c lowering effect of sitagliptin was greater in male than female (P value = 0.000). CONCLUSION: In this study, HbA1c was effectively lowered in 62% of the patients. The factors that affect the efficacy of sitagliptin were BMI, body fat (kg) body fat (%), and sex. Based on these results, we conclude that sitagliptin lowers glucose more effectively in non-obese male patients. |
| Key Words:
Dipeptidyl-peptidase IV inhibitors, Sitagliptin, Type 2 diabetes mellitus |
|
PDF Links
Full text via DOI
Download Citation
